Food and Drug Administration

Anti-Infective Drugs Advisory Committee

Pediatric Subcommittee

June 11, 2003


Neonatal Hyperbilirubinemia: Historical Background and Selected Recent Research Findings, Dr. Thomas Newman, MD, MPH, UCSF (HTM) (PPT)

Efficacy of Strategies for Predicting Hyperbilirubinemia - NEMC Evidence Report, Dr. Stanley Ip, MD (HTM) (PPT)

Management of Neonatal Hyperbilirubinemia - Methods of the AHRQ Evidence Report, Dr. Joseph Lau, MD, Tufts-New England Medical Center EPC (HTM) (PPT)

Accuracy of Transcutaneous Bilirubin Measurement - NEMC Evidence Report, Dr. Rebecca O'Brien, MD, Tufts-New England Medical Center (HTM) (PPT)

Phototherapy-A Review, Dr. William Oh, MD, Brown Medical School (HTM) (PPT)

Warning! Bilirubin is a Neurotixin - Who is Keeping Newborns Safe From the Hazards of Jaundice?, Sue Sheridan, PICK (HTM) (PPT)

Kernicterus Surveillance, Drs. Yeargin and Allsoff, CDC (HTM) (PPT)

Metalloporphyrin Heme Oxygenase Inhibitors, Dr. David Stevenson, MD, Stanford University School of Medicine (HTM) (PPT)

Ethical Issues: Hyperbilirubinemia and drug Development in the Term and Near-Term Newborn Infant, Dr. Robert Nelson, MD, PhD, University of Pennsylvania (HTM) (PPT)

Open Public Hearing

Pre-Discharge Bilirubin Screening to Prevent Adverse Outcomes of Neonatal Hyperbilirubinemai, Dr. Vinod Bhutania, MD and Dr. Lois Johnson, MD, University of Pennsylvania (HTM) (PPT)

Beyond Reliance on Vigilance and Evidenc-Based Medicine - A Systems Perspective on Identifying Hyperbilirubinemia, Dr. Martin Hatlie, JD, Partnership for Patient Safety (HTM) (PPT)